

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1 - 28. (Cancelled)

29. (Previously presented) A cell suspension produced according to a method comprising the steps of:

- (a) physically and/or chemically dissociating cellular stratum in a tissue sample, to provide cells suitable for grafting to a patient;
- (b) harvesting the cells in the presence of a nutrient solution, the harvested cells having the potential to include cell conglomerates; and
- (c) filtering the cells in nutrient solution to remove cell conglomerates, wherein the resulting cell suspension is free of xenogenic serum and of cell conglomerates, the cells remain viable, and the suspension is suitable for direct application to a region on a patient undergoing tissue grafting.

30-33. (Cancelled)

34. (New) A cell suspension according to claim 29, the suspension being distributed on a patient tissue site undergoing tissue grafting.

35. (New) A cell suspension according to claim 29 comprising the further step of:

- (d) administering the suspension directly to a region on the patient that requires a cell graft.

36. (New) A cell suspension according to claim 35 wherein the tissue sample is obtained from the patient that requires a cell graft.

37. (New) A cell suspension according to claim 35 wherein the cell suspension is distributed relatively evenly over the graft region.

38. (New) A cell suspension according to claim 35 wherein the cell suspension is obtained perioperatively.

39. (New) A cell suspension according to claim 35 wherein the cell suspension contains cells present in a ratio to each other comparable to those in the donor sample.

40. (New) A suspension according to claim 39 wherein the cells include keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes.

41. (New) A suspension according to claim 40 wherein the cells are substantially viable.

42. (New) A cell suspension according to claim 37 wherein the cell suspension is sprayed, spread, pipetted, or painted onto the tissue site.

43. (New) A cell suspension according to claim 35 wherein the cell suspension is obtained perioperatively from a tissue sample from the patient that requires a cell graft, contains cells present in a ratio to each other comparable to those seen in the donor sample, and is sprayed, spread, pipetted, or painted onto the tissue site to provide an even distribution over the graft region.

44. (New) A cell suspension produced according to a method comprising the steps of:

- (a) obtaining a tissue sample from a site on a donor in need of a tissue graft;
- (b) physically and/or chemically dissociating and removing cellular stratum from cells present in the sample;
- (c) harvesting the cells in the presence of a nutrient solution;
- (d) distributing the suspension on a site of the donor as an autologous tissue graft.

45. (New) A suspension according to claim 44 wherein the suspension is substantially free of cell conglomerates.

46. (New) A suspension according to claim 44 wherein the suspension is substantially free of xenogenic serum.

47. (New) A cell suspension according to claim 44 wherein the cell suspension is distributed relatively evenly over the graft region.

48. (New) A cell suspension according to claim 47 wherein the cell suspension is obtained peroperatively.

49. (New) A cell suspension according to claim 44 wherein the cell suspension contains cells present in a ratio to each other comparable to those seen in the donor sample.

50. (New) A suspension according to claim 49 wherein the cells are comprise keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes.

51. (New) A suspension according to claim 50 wherein the cells are substantially viable.

52. (New) A cell suspension according to claim 47 wherein the cell suspension is sprayed, spread, pipetted, or painted onto the tissue site.

53. (New) A cell suspension according to claim 44 wherein the cell suspension is obtained peroperatively, contains cells present in a ratio to each other comparable to those seen in the donor sample, and is sprayed, spread, pipetted, or painted onto the tissue site to provide an even distribution over the graft region.

54. (New) A cell suspension produced by a method comprising obtaining cells from a patient in need of a tissue graft, providing the cells in nutrient solution in a manner that is substantially

free of cellular stratum, xenogenic serum, and cell conglomerates, the suspension being distributed in apposition to the site of the recipient as a tissue graft.

55. (New) A suspension according to claim 54 wherein the suspension is distributed relatively evenly over the graft region.

56. (New) A cell suspension according to claim 54 wherein the cell suspension is obtained perioperatively.

57. (New) A cell suspension according to claim 54 wherein the cell suspension contains cells present in a ratio to each other comparable to those seen in the donor sample.

58. (New) A suspension according to claim 57 wherein the cells comprise keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes.

59. (New) A suspension according to claim 58 wherein the cells are substantially viable.

60. (New) A cell suspension according to claim 55 wherein the cell suspension is sprayed, spread, pipetted, or painted onto the tissue site.

61. A cell suspension comprising cells derived from a tissue site of a donor and produced by a method that provides a suspension comprising:

- (a) autologous cells substantially lacking cellular stratum;
- (b) the cells being provided in a nutrient solution free of xenogenic serum and of cell conglomerates;
- (c) the cells being viable, and the suspension being adapted for direct application to a region of the donor as a tissue graft, and
- (d) the cell population being substantially the same as the tissue site.

62. (New) A suspension according to claim 61 wherein the suspension is distributed relatively evenly over the graft region.

63. (New) A cell suspension according to claim 61 wherein the cell suspension is obtained perioperatively.

64. (New) A cell suspension according to claim 61 wherein the cell suspension contains cells present in a ratio to each other comparable to those seen in the donor sample.

65. (New) A suspension according to claim 64 wherein the cells comprise keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes.

66. (New) A suspension according to claim 65 wherein the cells are substantially viable.

67. (New) A cell suspension according to claim 62 wherein the cell suspension is sprayed, spread, pipetted, or painted onto the tissue site.

68. (New) A cell suspension produced by a method sufficient to provide the cells in nutrient solution, substantially free of cellular stratum, xenogenic serum, and cell conglomerates, the suspension serving as a graft in apposition to the body of a recipient in need of a tissue graft.

69. (New) A suspension according to claim 68 wherein the suspension is distributed relatively evenly over the graft region.

70. (New) A cell suspension according to claim 69 wherein the cell suspension is obtained perioperatively.

71. (New) A cell suspension according to claim 69 wherein the cell suspension contains cells present in a ratio to each other comparable to those seen in the donor sample.

72. (New) A suspension according to claim 71 wherein the cells comprise keratinocyte basal cells, Langerhans cells, fibroblasts and melanocytes.

73. (New) A suspension according to claim 72 wherein the cells are substantially viable.

74. (New) A cell suspension according to claim 69 wherein the cell suspension is sprayed, spread, pipetted, or painted onto the tissue site.